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AbstrACt
Objective To quantitate the 2016 global and national 
burden of chronic kidney disease (CKD) attributable to 
ambient fine particulate matter air pollution ≤ 2.5 μm in 
aerodynamic diameter (PM
2.5).
Design We used the Global Burden of Disease (GBD) study 
data and methodologies to estimate the 2016 burden of 
CKD attributable to PM
2.5 in 194 countries and territories. 
Population-weighted PM2.5 levels and incident rates of CKD 
for each country were curated from the GBD study publicly 
available data sources.
setting GBD global and national data on PM
2.5 and CKD.
Participants 194 countries and territories.
Main outcome measures We estimated the attributable 
burden of disease (ABD), years living with disability (YLD), 
years of life lost (YLL) and disability-adjusted life-years 
(DALYs).
results The 2016 global burden of incident CKD attributable 
to PM
2.5 was 6 950 514 (95% uncertainty interval: 5 
061 533–8 914 745). Global YLD, YLL and DALYs of CKD 
attributable to PM2.5 were 2 849 311 (1 875 219–3 983 941), 
8 587 735 (6 355 784–10 772 239) and 11 445 397 (8 380 
246–14 554 091), respectively. Age-standardised ABD, YLL, 
YLD and DALY rates varied substantially among geographies. 
Populations in Mesoamerica, Northern Africa, several 
countries in the Eastern Mediterranean region, Afghanistan, 
Pakistan, India and several countries in Southeast Asia were 
among those with highest age-standardised DALY rates. For 
example, age-standardised DALYs per 100 000 were 543.35 
(391.16–707.96) in El Salvador, 455.29 (332.51–577.97) 
in Mexico, 408.41 (283.82–551.84) in Guatemala, 238.25 
(173.90–303.98) in India and 178.26 (125.31–238.47) in Sri 
Lanka, compared with 5.52 (0.82–11.48) in Sweden, 6.46 
(0.00–14.49) in Australia and 12.13 (4.95–21.82) in Canada. 
Frontier analyses showed that Mesoamerican countries had 
significantly higher CKD DALY rates relative to other countries 
with comparable sociodemographic development.
Conclusions Our results demonstrate that the global toll 
of CKD attributable to ambient air pollution is significant 
and identify several endemic geographies where air 
pollution may be a significant driver of CKD burden. Air 
pollution may need to be considered in the discussion of 
the global epidemiology of CKD.
IntrODuCtIOn 
Several studies described substantial 
geographic variation in the burden of 
chronic kidney disease (CKD) that cannot 
be explained by traditional drivers including 
diabetes and hypertension.1–4 It was 
suggested that other risk factors including 
environmental pollution may explain these 
geographic variations.5 We recently charac-
terised fine particulate matter of <2.5 µm in 
aerodynamic diameter (PM2.5) as a novel risk 
factor for development and progression of 
kidney disease and described a linear rela-
tionship between exposure to levels of PM2.5 
and risk of incident CKD, kidney disease 
progression and end-stage renal disease.6 
The global burden of kidney disease attrib-
utable to ambient air pollution has not been 
previously described. A quantitative assess-
ment of the global burden of kidney disease 
attributable to air pollution might explain 
some of the geographic variation in burden 
of kidney disease, help identify endemic areas 
and contribute to the global and national 
discussions about the effect of environmental 
strengths and limitations of this study
 ► The study leveraged the availability of the Global 
Burden of Disease study data, which is the most 
comprehensive compilation and analysis of global 
health information available.
 ► The study quantitated the burden of chronic kid-
ney disease (CKD) attributable to air pollution using 
the combined measure of disability-adjusted  life-
years, which comprehensively captures the years of 
healthy life lost due to dying prematurely and to the 
years living with disability.
 ► For each estimate reported in this study, we also 
provide a measure of uncertainty (uncertainty inter-
vals) to reflect how much is known, but more impor-
tantly how much is not known.
 ► The burden was quantitated at the country level; the 
study does not provide subnational estimates of CKD 
burden.
 ► Global burden of disease estimates, while consid-
ered robust and reliable, are necessarily limited by 
the quality of the available data.
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pollution on non-communicable disease in general and, 
more specifically, on the potential impact of air pollution 
on the global epidemiology of CKD. In this work, we used 
the Global Burden of Disease (GBD) study methodologies 
to estimate the burden of CKD attributable to fine partic-
ulate matter air pollution in 194 countries and territo-
ries using the following measures: attributable burden of 
disease (ABD), years living with disability (YLD), years of 
life lost (YLL) and disability-adjusted life-years (DALYs).
MethODs
Global data sources
National PM2.5 exposure levels were obtained from 
publicly available 2016 GBD data.7–9 The GBD PM2.5 values 
are derived from the integration of satellite data, surface 
measurements, geographic data and a chemical transport 
model at a 1° (approximately 11 by 11 km at the equator) 
resolution, and then aggregated to national-level popu-
lation-weighted means to produce a national exposure 
estimate.7 8 Estimates of global and national incident 
rates, YLDs, YLLs, DALYs of CKD and their uncertainty 
levels were obtained from the publicly available 2016 
GBD.10 11 The GBD aims to use all accessible information 
on disease occurrence, natural history and severity that 
meets inclusion criteria, drawing on a large network of 
collaborators for subject matter expertise on disease and 
injury to generate internally consistent, comprehensive 
global health statistics on the burden of disease.12 GBD 
uses an integrative Bayesian meta-regression method 
that estimates a generalised negative binomial model 
for all epidemiological data through DisMod-MR 2.1 to 
compute GBD estimates of disease burden including 
YLDs, YLLs and DALYs.12 Estimates are generated using 
hierarchical modelling methodology that accounts for 
temporal, geospatial, sex, age and cause specific variance 
to establish attributable burden of disease across all levels 
of the GBD framework.10 13–16 Key to GBD estimates are 
the propagation of uncertainty through the modelling 
process, which incorporates uncertainty due to diversity 
in data sources, sparsity of data for some parts of the 
world, modelling choices and other factors that impact 
estimation such as the determination of disability weights. 
Detailed descriptions of overall GBD 2016 methodologies 
and specific CKD methodology have been provided else-
where.10 12–17 Population size was obtained from the GBD 
Population Estimates dataset.18 Country income classifi-
cations were obtained from the World Bank.19
PM2.5 risk estimation
PM2.5 risk estimation was obtained from prior work 
assessing the association of PM2.5 with kidney disease 
outcomes.6 Department of Veterans Affairs datasets were 
linked with the Centers for Disease Control and Preven-
tion’s National Environmental Public Health Tracking 
Network annual particulate matter estimates for the 
contiguous USA, which originates from Community Multi-
scale Air Quality modelled output.20 Time-dependent 
adjusted Cox proportional hazard survival models, where 
cohort participants’ exposure was updated annually and 
on movement in residence, were used to investigate 
the association between PM2.5 and time until incident 
estimated glomerular filtration rate (eGFR) <60 mL/
min/1.73 m2. Models were adjusted for age, race, sex, 
cancer, cardiovascular disease, chronic lung disease, 
diabetes mellitus, hyperlipidaemia, hypertension, eGFR 
at time of cohort entry, body mass index, smoking status, 
ACE inhibitor/angiotensin receptor blocker use, county 
population density, number of outpatient eGFR measure-
ments, number of hospitalisations and county percent in 
poverty. Restricted cubic spline analyses of PM2.5 suggested 
no deviation from linearity in the range of PM2.5 in the 
study (5.0–22.1 µg/m3). Alternate analyses using time 
zero exposure values and using National Aeronautics and 
Space Administration (NASA) data as an alternate expo-
sure source produced consistent results.21 22 Ambient 
sodium levels were investigated as a negative control, 
where there existed no biological bases to support an 
association with risk of incident CKD. Results for every 
IQR (the distance between the 25th and 75th percen-
tile; 0.046 µg/m3) increase in sodium showed a vanish-
ingly weak association, 0.99 (0.99–0.99). Results were 
consistent in sensitivity analyses that used ground-level 
measures only and that assessed potential confounding 
by shared regional characteristics.6 To estimate risk in 
each country, we relied on the PM2.5 pollution and risk 
relationship characterised in the prior study described 
above6 where PM2.5 levels ranged from 5.0 to 22.1 µg/m
3.6 
In this study, we took a conservative approach where we 
considered annual average PM2.5 exposure greater than 
22.1 µg/m3 to contribute the same amount of risk as an 
exposure of 22.1 µg/m3.7 23 This approach is supported 
by findings from GBD and several other studies where 
integrated exposure response functions suggest that risk 
of adverse health outcomes of PM2.5 pollution levels off 
(follows a near plateau morphology) at PM2.5 concentra-
tions exceeding 20–25 µg/m3.7 8 23
Population attributable fraction and AbD
The population attributable fraction (PAF) of CKD due 
to PM2.5 exposure above the theoretical minimum risk 
exposure level (TMREL) was calculated using an adapted 
GBD equation.14 This PAF can be interpreted as the 
proportion of incident CKD attributable to PM2.5 expo-
sure that exceeds the TMREL. The proportional hazards-
based equation for PAF in a country is:
 
 
PAF =
HR
(
x
)−HR(TMREL)
HR
(
x
)
 
 
where HR(x) is the HR for PM2.5 at the national expo-
sure level, and HR(TMREL) is the HR for PM2.5 at the 
TMREL. The TMREL was defined according to the GBD 
study methodologies.8 23 24 The TMREL was assigned as a 
uniform distribution of PM2.5 from 2.4 µg/m
3to 5.9 µg/
m3, which represents exposure values between the 
minimum and fifth percentiles of exposure distributions 
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from outdoor air pollution cohort studies included in the 
GBD anlayses.8 23 24 Levels under the TMREL were treated 
as contributing no risk.8 Results were repeated using the 
WHO Air Quality Guidelines for annual average of PM2.5 
concentration of 10 µg/m3 as the TMREL.25
Burden of CKD attributable to PM2.5 above the TMREL, 
as the number of incident CKD per year attributable to 
PM2.5 above the TMREL, was calculated using estimates 
from the 2016 GBD,13 from the equation:
  ABD = PAF ∗ IR ∗ population  
where PAF is the population attributable fraction, IR 
is the incident rate of CKD, and population is the size of 
the population of the country or territory in which the 
burden is being assessed.2 Results were repeated using 
the WHO TMREL.
YLD, YLL and DALYs
YLD, YLL and DALY values were estimated by multi-
plying the CKD-specific GBD values of the corresponding 
burden measure by the PAF,13 17 resulting in YLD, YLL 
and DALY values due to CKD attributable to PM2.5. YLD, 
YLL and DALY estimates due to CKD were obtained from 
the GBD results tool.10 11 The basis of their calculation is 
presented below; further information has been described 
elsewhere.13 17 Results were repeated using the WHO 
TMREL.
YLD due to CKD is calculated as:
  YLD = P ∗ DW  
where P is the prevalent cases of CKD in the population, 
and DW is the disability weight for CKD representative of 
the severity of its impact on a person’s life (0: no impact, 
to 1: the same as death). YLD due to CKD is a measure of 
the burden placed on a population due to the ill effects 
of living with CKD.26
YLL due to CKD is calculated using the equation:
  YLL = N ∗ L  
where N is the number of deaths due to CKD and L is the 
difference between age of death and average life expec-
tancy due to CKD. YLL due to CKD is a measure of the 
burden placed on a population due to dying prematurely 
from CKD. Estimates of the difference between average 
life expectancy and age of death from CKD come from a 
GBD set of age and location–year specific life tables.10 13–16
DALYs due to CKD is calculated using the equation:
 DALY = YLD + YLL  
The DALY due to CKD is a summary measure of YLD 
and YLL and represents the total years of healthy life lost 
due to ill health, disability or early death due to CKD.
Measure estimation and uncertainty
In order to incorporate the uncertainty in measurements 
used in our estimation, all measures were generated from 
a distribution of 10 000 predictions, where the median 
(uncertainty interval (UI): 2.5th–97.5th percentile) 
are reported. Predictions incorporated uncertainty 
by randomly sampling from, unless otherwise speci-
fied, constructed normal distributions of the relevant 
measures. Uncertainty was derived from the TMREL 
distribution, the SE of the PM2.5 beta estimate and the 
uncertainty of the incident rates, YLD, YLL and DALY 
from the GBD data. While accounting for variability in 
measures, measures sampled under 0 were set to 0. Values 
of 0 thus represent instances of estimated zero burden, 
reflective of areas where the corresponding PM2.5 levels 
are below the TMREL distribution or where uncertainty 
was enough to result in such estimates. Maps of age-stan-
dardised rates are presented. All analyses were performed 
in SAS Enterprise Guide V.7.1. Maps were generated 
using Arc Map 10 (ESRI, Redlands, California, USA). The 
circular layout image was generated using the Circos soft-
ware package.27
Frontier analysis
Frontier analysis was conducted as a quantitative meth-
odology to identify the lowest potentially achievable 
age-standardised DALYs on the basis of development 
status as measured by the Sociodemographic Index 
(SDI). SDI is a summary measure of a country or terri-
tory’s sociodemographic development; it is a composite 
measure of average income per person, educational 
attainment and total fertility rate in any given country. 
The minimum possible SDI is 0, while the maximum is 
100; it is comparable across geography and over time.28 
The DALYs frontier delineates the minimum DALY that 
could be achieved for every geography (country or terri-
tory) given its SDI. Distance from the frontier is termed 
effective difference; if a country or territory exhibits a 
large effective difference from the frontier given its SDI, 
then this likely suggests unrealised opportunities for gains 
or improvement (reduction in DALYs) that should be 
possible based on the country or territory’s state on the 
development spectrum. A data envelope analysis, which 
allows for non-linear frontiers, using the free disposal 
hull method was developed to produce a frontier for age 
adjusted DALYs.28 29 In order to account for uncertainty, 
we used 1000 bootstrapped samples of the data, randomly 
sampling with replacement from all countries and terri-
tories. LOESS regression was then used on this result to 
produce a smoothed frontier.28 Super-efficient countries 
were excluded, to remove the influence of outliers, in the 
generation of the frontier.28 Absolute distances from the 
frontier of each country are reported as effective differ-
ence, where any countries with lower DALYs than the 
frontier were assigned a 0 distance.
In order to account for the effect of variation in 
prevalence of primary drivers of CKD (hypertension 
and diabetes) on differences in overall DALY rates, we 
repeated the frontier analysis following a decomposition 
analysis to generate risk deleted cause-specific age-stan-
dardised DALY rates of CKD attributable to PM2.5,
17 where 
risks deleted were hypertension and diabetes. Diabetes 
and hypertension cause-specific CKD rates were obtained 
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from the 2016 GBD, which were then subtracted from 
overall rates and then multiplied by the PAF.11 The risk 
deleted DALY can be conceptualised by the formula:
  DALYO = DALYDHO ∗
(
1− PAFDH
)
  
where DALYO is the DALY due to other causes, DALYDHO 
is the DALY due to all three causes and PAFDH is the 
population attributable fraction due to diabetes and 
hypertension.
Patient involvement
No patients were involved in developing the aims, design 
or implementation of this study. No patients were involved 
in the interpretation of study results, or write up of the 
manuscript.
resuLts
Global burden of kidney disease attributable to air pollution
In 2016, the global annual burden of incident CKD 
attributable to elevated PM2.5 was, in 1000s, 6950.51 (95% 
uncertainty interval: 5061.53–8914.74). ABD rate per 
100 000 people was 94.29 (68.67–120.94), and age-stan-
dardised ABD rate per 100 000 was 101.39 (74.49–129.69) 
(table 1).
The 2016 global YLD, YLL and DALYs of CKD attribut-
able to elevated PM2.5 are reported in table 2 as absolute 
values in 1000s, rates per 100 000 population and age-stan-
dardised rates per 100 000. Age-standardised rates for 
YLD, YLL and DALYs were 40.97 (26.84–57.11), 122.71 
(90.36–153.52) and 163.69 (120.58–207.28), respectively 
(table 2).
burden of kidney disease attributable to air pollution at the 
national level
ABD, YLD, YLL and DALYs reported as absolute values, 
as rates per 100 000 population and as age-standardised 
rates per 100 000 population for 10 most populated coun-
tries (tables 1 and 2) and for 194 countries and territories 
are provided in online supplementary table 1 and online 
supplementary table 2.
Among the 10 most populated countries in the world, 
India followed by China had the highest attributable burden 
of incident CKD due to air pollution globally (ABD=10 92.52, 
UI=791.38–1407.28, and 766.73, 558.72–985.14, in 1000s, 
respectively). India also outranked China in estimates stan-
dardised by population size and age distribution (table 1). 
Age-standardised ABD in the 10 most populated countries 
showed Nigeria, Bangladesh and India having high burden 
exceeding 100 incident cases of CKD per 100 000 popula-
tion (table 1). Age-standardised ABD per 100 000 population 
varied substantially among geographies, where it was highest 
in Guinea-Bissau, El Salvador, Senegal, Togo, Benin, Mauri-
tania, Chad, Ghana, Niger and Mali (online supplementary 
Table 1 Attributable burden of chronic kidney disease (ABD) associated with PM2.5 exposure globally and for the top 10 most 
populous countries
Country PM2.5 (μ g/m
3) ABD (in 1000s) ABD (per 100 000)
Age-standardised 
ABD (per 100 000)
Global 42.27 6950.51
(5061.53–8914.74)
94.29
(68.67–120.94)
101.39
(74.49–129.69)
China 57.2 766.73
(558.72–985.14)
55.42
(40.39–71.21)
48.98
(35.52–63.01)
India 72.6 1092.52
(791.38–1407.28)
83.30
(60.34–107.29)
108.21
(77.99–139.22)
US 8.3 163.49
(88.76–262.78)
50.53
(27.44–81.22)
35.44
(19.39–57.44)
Indonesia 15.0 76.81
(53.66–103.42)
29.81
(20.83–40.15)
37.38
(26.05–50.06)
Brazil 11.1 69.03
(45.11–99.44)
33.21
(21.70–47.84)
36.57
(23.68–52.72)
Pakistan 63.0 107.43
(78.85–137.04)
56.83
(41.71–72.49)
89.17
(64.66–114.14)
Nigeria 36.9 195.23
(141.44–250.95)
106.98
(77.51–137.52)
200.28
(145.24–261.20)
Bangladesh 87.0 136.17
(99.56–174.46)
84.60
(61.86–108.39)
121.08
(88.55–156.18)
Russia 15.8 170.89
(118.90–229.76)
115.38
(80.27–155.12)
82.87
(57.99–111.67)
Japan 13.1 134.56
(91.13–186.81)
104.88
(71.03–145.60)
44.79
(30.61–61.70)
PM2.5, fine particulate matter <2.5 µm.
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table 1 , figure 1). Mapping the geographic distribution of 
age-standardised ABD rates showed high burden in Meso-
america, several countries in Central and South Africa, 
Mongolia and several countries in the Far East and the 
Eastern Mediterranean region (figure 1). Countries with 
the lowest age-standardised ABD per 100 000 population 
included Canada, Greenland, several countries in Scandi-
navia, Brunei, New Zealand and Australia (online supple-
mentary table 1 , figure 1).
Years living with disability
Estimates for YLD in absolute terms, rates per 100 000 
population and age-standardised YLL rates are provided in 
table 2 for the 10 most populated countries and in online 
supplementary table 2 for 194 countries and territories. 
Among the 10 most populated countries, Nigeria had the 
highest age-standardised YLD rate per 100 000 population 
(YLD=71.93, UI=45.61–103.27), followed by Bangladesh 
(45.58, 28.89–64.56) and then India (45.40, 29.19–64.54). 
Among all countries, Iraq, Afghanistan, Guinea-Bissau, 
Senegal, Chad, Turkey, Mali, Niger and Yemen had the 
highest age-standardised YLD rate per 100 000 population 
(online supplementary table 2 , figure 2).
Years of life lost
Estimates for YLL in absolute numbers, rates per 100 000 
population and age-standardised rates per 100 000 popula-
tion for 10 most populated countries and for 194 countries 
and territories are provided in table 2 and online supple-
mentary table 2, respectively. Among the 10 most popu-
lated countries, Pakistan had the highest age-standardised 
YLL per 100 000 population (YLL=215.59, UI=123.95–
322.52), followed by India (192.55, 138.73–249.04) and 
then Bangladesh (137.57, 98.14–179.69). Among all coun-
tries and territories, Afghanistan, El Salvador, Nicaragua, 
Mexico, Honduras, Philippines, Guatemala, Iraq, Palestine 
and Belize had the highest age-standardised YLL per 100 000 
population (online supplementary table 2 , figure 3).
Disability-adjusted life-years
Among the 10 most populated countries, India had the 
highest DALY (DALY=2502.15, UI=1827.96–3204.77 in 
1000s), followed by China (1651.72, 1212.35–2103.21) and 
then Pakistan (342.45, 213.87–492.17) (table 2). DALY rates 
per 100 000 population showed that India remained on top 
with DALY rate of 190.77 (UI=139.37–244.33), followed 
by Pakistan with DALY rate of 181.14 (UI=113.12–260.33), 
then Bangladesh with DALY rate of 136.84 (UI=99.13–
176.20) (table 2). Age-standardised DALY rates showed 
Pakistan leading, followed by India, then Bangladesh with 
age adjusted DALY rates of 254.25 (UI=157.33–365.23), 
238.25 (UI=173.90–303.98) and 183.21 (132.76–236.87), 
respectively.
Among all countries and territories, those with the highest 
age-standardised DALY rates included Afghanistan, El 
Salvador, Nicaragua, Mexico, Honduras, Iraq, Guatemala, 
Philippines, Palestine and Belize (online supplementary table 
2). Mapping the geographic distribution of age-standardised 
DALY rates across the globe showed populations in Meso-
america, Northern Africa, South Africa, several countries in 
the Eastern Mediterranean Region, Afghanistan, Pakistan, 
India and several countries in Southeast Asia were among 
those with highest age-standardised DALY rates (figure 4). For 
example, age-standardised DALYs per 100 000 were 543.35 
(391.16–707.96) in El Salvador, 455.29 (332.51–577.97) 
Figure 1 Age-standardised burden (ABD) of incident chronic kidney disease attributable to PM2.5 per 100 000 population. ATG, 
Antigua and Barbuda; FSM, Federated States of Micronesia; Isl, island; LCA, Saint Lucia; PM2.5, fine particulate matter <2.5 µm; 
TLS, Timor-Leste; TTO, Trinidad and Tobago; VCT, Saint Vincent and the Grenadines.
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in Mexico, 408.41 (283.82–551.84) in Guatemala, 295.39 
(203.17–401.39) in Jordan, 273.55 (184.84–379.35) in Egypt, 
264.23 (181.58–360.76) in Morocco, 259.46 (189.72–330.98) 
in South Africa, 205.12 (148.73–264.89) in Thailand, 183.21 
(132.76–236.87) in Bangladesh and 178.26 (125.31–238.47) 
in Sri Lanka. The map identified Canada, several northern 
European and Scandinavian countries, New Zealand and 
Australia as having lowest estimates of age-standardised 
DALY rates. For example, age-standardised DALY rates were 
5.52 (0.82–11.48) in Sweden, 6.46 (0.00–14.49) in Australia, 
and 12.13 (4.95–21.82) in Canada (figure 4).
Frontier analysis
We developed a frontier analysis to identify countries and 
territories that exhibited the least burden of kidney disease 
attributable to particulate matter air pollution given their 
Figure 2 Age-standardised years living with disability (YLD) due to incident chronic kidney disease attributable to PM2.5 per 
100 000 population. ATG, Antigua and Barbuda; FSM, Federated States of Micronesia; Isl, island; LCA, Saint Lucia; PM2.5, fine 
particulate matter <2.5 µm; TLS, Timor-Leste; TTO, Trinidad and Tobago; VCT, Saint Vincent and the Grenadines.
Figure 3 Age-standardised years of life lost (YLL) due to incident chronic kidney disease attributable to PM2.5 per 100 000 
population. ATG, Antigua and Barbuda; FSM, Federated States of Micronesia; Isl, island; LCA, Saint Lucia; PM2.5, fine particulate 
matter <2.5 µm; TLS, Timor-Leste; TTO, Trinidad and Tobago; VCT, Saint Vincent and the Grenadines.
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SDI. The analysis provides a comparative quantitative assess-
ment of the potential reduction in CKD burden that might be 
achievable in each country given their social and economic 
development. Most importantly, for each SDI, this analysis 
identifies exemplar countries at the frontier (with lowest 
DALYs for their SDI) and countries with the highest DALYs 
for their SDI. The effective difference between the frontier 
and the highest DALYs given an SDI represents a hypothet-
ical magnitude of potential improvement in impact of air 
pollution on burden of CKD in a given country. Frontier anal-
ysis of age-adjusted DALYs are presented in figure 5. Online 
supplementary table 3 provides the effective difference from 
the frontier for each country given that country SDI; coun-
tries with the largest effective difference were El Salvador, 
Afghanistan, Mexico, Nicaragua, Honduras, Philippines, 
Iraq, Guatemala and Palestine. Among countries with an 
SDI <0.3, Somalia, Niger, Liberia, the Democratic Republic 
of Congo, Mozambique and Burundi had age-standardised 
DALY rates that are close to the frontier with an effective 
difference of less than 10. Afghanistan, Guinea-Bissau and 
Chad also had an SDI <0.3; however, they exhibited relatively 
high age-standardised DALY rates and effective difference 
from the frontier that exceeded 100 representing a large 
gap in performance vis-à-vis other countries with compa-
rable resources. Among reasonably well-resourced countries 
with an SDI >0.7, Mexico, Mauritius, The United Arab Emir-
ates, Saudi Arabia, Turkmenistan, Venezuela, South Africa, 
Bahrain and Mongolia had an effective difference from the 
frontier of more than 200 representing potential unrealised 
opportunities for progress in those countries given their 
resources.
To further evaluate the frontier independent of poten-
tial contamination by other strong drivers of CKD such as 
diabetes—where it is a major driver in Mexico30—and hyper-
tension, we rebuilt the entire frontier following a decompo-
sition analysis of risk-deleted cause-specific DALYs where we 
risk-deleted DALYs caused by diabetes and hypertension. 
This analysis yielded consistent results (online supplemen-
tary figure 1); specifically, that several countries including 
Mesoamerica exhibited significant effective difference from 
the frontier suggesting a disproportionally higher PM2.5 
attributable DALYs than would be expected by their SDI 
(online supplementary figure 1).
burden of CKD attributable to PM2.5 levels above the WhO limit 
of 10 µg/m3
All the primary analyses were developed considering risk 
attributable to exposure levels of PM2.5 above a uniform 
distribution between 2.4 µg/m3and 5.9 µg/m3 representing 
exposure values between the minimum and fifth percen-
tiles of exposure distributions from outdoor air pollution 
studies.7 8
We repeated all the analyses where we considered risk 
attributable to exposure levels of PM2.5 above the WHO limit 
of 10 µg/m3 (using the alternate scenario where the theo-
retical minimal risk exposure level was set at 10 µg/m3).6 
The estimates describe the burden of kidney disease—glob-
ally and at the national level—that is attributable to PM2.5 
concentrations in excess of the WHO limit. The geographic 
distribution of burden was consistent with the primary 
results (online supplementary tables 4 and 5). The results 
from this analysis necessarily underestimate the true burden 
as they—by definition—ignore PM2.5-related risk below the 
WHO limit but might be informative to policy makers and 
relevant stakeholders in estimating the burden of CKD that 
Figure 4 Age-standardised disability-adjust life-years (DALYs) due to incident chronic kidney disease attributable to PM2.5 per 
100 000 population. ATG, Antigua and Barbuda; FSM, Federated States of Micronesia; Isl, island; LCA, Saint Lucia; PM2.5, fine 
particulate matter <2.5 µm; TLS, Timor-Leste; TTO, Trinidad and Tobago; VCT, Saint Vincent and the Grenadines.
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could be avoided should targeting the WHO limit become a 
policy goal.
DIsCussIOn
In this work, we provide a quantitative analysis of the 
global burden of CKD attributable to air pollution in 194 
countries and territories. The results describe the annual 
incidence of kidney disease attributable to air pollution 
globally and at the national level and provide a quantita-
tive assessment of the YLD due to kidney disease, YLL due 
to early mortality from kidney disease and the combined 
comprehensive measure of DALYs (years of healthy life 
lost, due to dying prematurely and and to the YLD) of 
kidney disease attributable to air pollution. The global 
toll of CKD attributable to air pollution is significant with 
6.9 million incident cases of CKD per year, 94 cases per 
100 000 population per year and 11.4 million DALYs per 
year. The findings suggest substantial geographic variation 
and identify geographies where the toll of air pollution 
may be a significant driver of the epidemiology of kidney 
disease. Our analyses also suggest disproportionately 
higher PM2.5 DALYs from kidney disease in several coun-
tries including Mesoamerica than would be expected for 
their SDI.
According to the GBD study, global age-standardised 
DALY rates attributable to PM2.5 are 1521 per 100 000.
31 
Our estimates of PM2.5 CKD DALYs were 164, representing 
10.7% of the total global DALYs—years of healthy life 
lost—attributable to air pollution.31 Our analyses suggest 
that the overall burden of kidney disease attributable to 
air pollution is shaped by the epidemiological transition.32 
Among countries that are poor with a high burden of 
communicable diseases and reduced life expectancy (eg, 
several countries in the African continent), we observed 
a lower global ranking for YLL  than YLD (figures 2 and 
3), reflecting increased probability of early loss of life 
from other diseases not related to air pollution. The 
corollary observation is that countries that are relatively 
more developed including Mesoamerica, South America 
(including Venezuela, Gynae, Surinam and Bolivia), Paki-
stan, India and several countries in southeast Asia ranked 
in the highest decile for YLL but not in YLD, reflecting 
Figure 5 Frontier analysis of age-standardised disability-adjusted life-years (DALYs) rate per 100 000 population by 
Sociodemographic Index. Countries with the top 10% effective difference are labelled. Countries are coloured by region.
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much earlier loss of life attributable to air pollution-re-
lated kidney disease (figures 2 and 3). The results suggest 
that as countries journey forward along the path of the 
epidemiological transition, the contribution of air pollu-
tion to non-communicable disease mortality in general, 
and more specifically CKD, becomes more pronounced. 
Unfortunately, CKD has been largely ignored in the global 
and WHO discussion of non-communicable diseases33–36; 
CKD and its environmental drivers should feature on the 
national, international development, and global health 
agendas36–38 and should be assigned a priority commen-
surate with its ascending rank among the global burden 
of diseases.2 10 13–16 39–44
Our results show substantial geographic variation in 
the global burden of CKD attributable to air pollution 
(figure 4), where low-income and lower middle-income 
countries are most affected (figures 6 and 7). Air pollu-
tion is a significant global problem with well documented 
transboundary health impacts due to international trade 
and atmospheric pollutant transport45; it results in an esti-
mated 4.2 million deaths per year and is worsening espe-
cially in low-income and middle-income countries.15 31 37 46 
This is consistent with findings from the State of Global Air 
2017 report where the largest increases in air pollution-re-
lated death were in rapidly industrialising low-income and 
middle-income countries.31 37 The global burden of CKD 
Figure 6 Plot showing burden of CKD attributable to PM2.5 in 194 countries and territories. Heat map tracks show percentiles, 
which from inside to outside represent the YLL, YLD, ABD, effective difference and DALY. Scatter plot represents the DALYs (in 
open circles) and effective difference (in closed circles) percentile, with a reference line at the median. Values are graded, from 
low to high, as blue to red (on the Brewer palette). Countries are represented by their three-character country code. Regions 
are ordered from low to high burden clockwise. ABD, attributable burden of disease; DALY, disability-adjusted life-years; DIFF, 
effective difference; CKD, chronic kidney disease; NA, North America; PM2.5, fine particulate matter <2.5 µm; YLD, years living 
with disability; YLL, years of life lost.
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is increasing and its rank as a contributor to disability 
and death is ascending43; it disproportionately impacts 
low-income and middle-income countries,1 36 43 47 which 
are least equipped to provide costly but life-saving CKD 
care.33 34 While diabetes mellitus and hypertension are 
the leading causes of CKD in high and upper middle-in-
come countries, a significant proportion of CKD cannot 
be explained by these traditional causes in low and lower 
middle-income countries where environmental expo-
sures loom prominently as potential drivers of non-com-
municable diseases including CKD.36 37 48–50 In an elegant 
recent editorial, Jha and Modi51 reflected on the rise of 
kidney failure death in India and suggested that a sizeable 
portion of kidney failure is not due to traditional drivers 
(diabetes mellitus) and advocated for a research agenda 
to identify the drivers of this increased incidence of 
kidney failure and kidney failure death. Others have also 
advocated for greater understanding and larger emphasis 
of the role of environmental air pollution in non-commu-
nicable diseases and specifically kidney disease.37 49 The 
rise of CKD of unknown origin in Mesoamerica and other 
geographies including India and Sri Lanka illustrates the 
need for a broader and more comprehensive evaluation 
of potential risk factors for development and progression 
of kidney disease.36 52
Our frontier analysis provides a blueprint to compara-
tively evaluate the CKD DALYs attributable to air pollution 
in countries with similar resources. The analysis identifies 
a cluster of countries with substantially higher CKD DALYs 
than would be expected for their place on the development 
spectrum. The clustering of countries including Mesoamer-
ican countries with a high CKD DALYs gap attributable 
to air pollution is likely not random and (A) supports the 
prescient hypothesis put forth by Orantes-Navarro et al52 for 
inclusion of environmental air pollution—among others—
as a potential risk factor for CKD of unknown cause—a so far 
elusive disease entity, vibrantly discussed among luminaries 
in the field36 42 53–62— and (B) potentially represents unreal-
ised opportunity for improved performance through inter-
ventions in the form of laws, health and economic policy 
measures, reprioritisation and alignment of resources, tech-
nological transition and other devices that would ultimately 
close the DALYs gap. Similarly, our analysis identifies exem-
plar countries where performance for the county’s level of 
development is considered leading (at the frontier pushing 
the envelope), the identification of these exemplars provides 
a window for better understanding of the potential drivers 
for success34 and determination whether advocacy and wider 
adoption of these drivers by other countries might yield 
decreased CKD burden.38
While our analyses described the global and national 
burden of kidney disease attributable to PM2.5 air pollu-
tion, consideration of the impact of other air pollut-
ants (ie, nitrogen oxides, ozone, carbon monoxide, 
PM10 and others),
48 a higher spatial resolution analysis 
at the subnational level and a greater understanding of 
temporal trends over the years (eg, an annual global CKD 
burden report that would track the contributions of all 
risk factors over time) are certainly needed to develop a 
better understanding of the epidemiology of CKD driven 
by air pollution. Future work should revisit this question 
to provide updated estimates of the burden of CKD attrib-
utable to ambient air pollution when updated and more 
accurate estimates for PM2.5 and CKD are available across 
the PM2.5 exposure spectrum for incorporation in integra-
tive meta-regression methods.23 63 64
Three hypotheses have been proposed to explain the 
mechanisms by which PM2.5 may play a role in the devel-
opment of CKD: (A) Inhaled particular matter may result 
in pulmonary inflammation, which could then lead to 
systematic inflammation, (B) pollutants may also induce 
disturbances in respiratory autonomic nervous system and 
subsequently provoke systemic disturbances resulting in 
kidney damage and (C) evidence has also suggested that 
inhaled fine particulate matter when sufficiently small may 
enter the bloodstream and subsequently interact with kidney 
tissue.65 66 Furthermore, the association between PM2.5 and 
CKD has been supported by other work. In a recent study 
of the US Medicare population by Bragg-Gresham et al, a 
4 µg/m3 increase in levels of PM2.5 was associated with higher 
prevalence of diagnosed CKD (prevalence ratio=1.03; 
95% CI 1.02 to 1.05).67 In a study of 100 629 adult non-CKD 
Taiwanese residents by Chan et al, a 10 µg/m3 increase in 
PM2.5 was associated with an increased risk of incident CKD 
(HR: 1.06; 95% CI 1.02 to 1.10).68
This study has several limitations. Our analyses do 
not account for the composition and toxic content of 
PM2.5; however, studies have shown that estimates using 
non-specific PM2.5 biomass alone will underestimate the 
burden of kidney disease attributable to air pollution.7 8 46 
Furthermore, we considered that risk plateaued for PM2.5 
concentrations above 22 µg/m3; this likely yielded conser-
vative estimate of the true burden of CKD attributable 
to air pollution. Our estimates of CKD attributable to 
PM2.5 at the global and national levels reflect the influ-
ence of PM2.5 levels across the globe and of demography 
and underlying CKD rates. Our analyses were performed 
at the global and national level where we assigned PM2.5 
exposure and generated incident rates of CKD for every 
country and territory; thus, our analyses do not provide 
Figure 7 Age-standardised CKD DALYs (per 
100 000) attributable to PM2.5 by World Bank income 
classification. CKD, chronic kidney disease; DALY, disability-
adjusted life-years; PM2.5, fine particulate matter <2.5 µm.
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further insight into the subnational level. We relied on 
estimates for incident CKD generated by the GBD study 
group, and while those Bayesian estimates are considered 
reliable and robust, they are necessarily limited by the 
quality of the available data.69 Furthermore, variability and 
inconsistency of data collection methods and tools across 
the countries could influence geographic variations.69 
Inaccuracies in prediction of population exposure levels 
may have introduced bias.70 We did not have data on 
indoor air pollutants, which may have resulted in misclas-
sification of exposure or confounding of observed asso-
ciations. Collinearity with other pollutants, geographic 
heterogeneity in effect, seasonal variation and lagged 
effect of exposure may have biased the association.71 72 To 
generate the estimates provided in this report, we relied 
on risk estimates generated in prior work6 and while the 
analytic strategies were robust including the application of 
negative controls, the possibility of residual confounding 
cannot be eliminated. Causal interpretations should be 
made with caution. Small differences in estimated risk 
could have profound impacts on estimated burden. In 
the GBD, CKD of unknown origin is not currently part 
of the casual framework; available evidence on how PM2.5 
is associated with CKD of different aetiologies is limited 
and, if different, could have biased results.
Key strengths include leveraging the availability of the 
2016 GBD data, which is the most comprehensive compi-
lation and analysis of global health information avail-
able; we also employed GBD methodologies including 
the concept of DALY to capture the burden of disease 
across the globe and a measure of uncertainty (to reflect 
how much we know and how much we do not know). We 
also developed a frontier analysis to enable comparative 
evaluation among countries with similar SDI, and finally, 
we repeated all analyses using an alternative scenario 
where we considered the WHO air quality standards as 
counterfactual.
In sum, our results show that the global toll of CKD 
attributable to air pollution is significant. The burden 
varies substantially by geography. Air pollution might 
be a contributing risk factor and might partially explain 
the rise in the incidence of CKD of unknown cause in 
some geographies around the world. As countries further 
develop and industrialise and travel along the path of 
the epidemiological transition, the rise in air pollution 
related non-communicable disease and specifically kidney 
disease should be reflected on the global health agendas.
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